Our lab is dedicated to the understanding of mechanisms that enable the destruction of disease-relevant proteins in the cytoplasm. Our interests centre on the newly-identified antibody receptor, TRIM21, which promotes selective degradation of antibody-bound targets in the cytoplasm. We have a particular interest in neurodegenerative diseases, where proteins are frequently found in altered conformations. Using antibodies and TRIM21 provides an opportunity to selectively target pathological protein assemblies whilst leaving native protein intact.
We are located in the UK Dementia Research Institute, situated within the Department of Clinical Neurosciences at the University of Cambridge.